Hoppe U C
Klinik III für Innere Medizin der Universität zu Köln, Kerpener Str. 62, 50937, Köln.
Internist (Berl). 2006 Dec;47(12):1289-93. doi: 10.1007/s00108-006-1749-x.
Elevated heart rate is associated with increased cardiovascular mortality. Heart rate reduction optimises myocardial oxygen consumption and decreases angina pectoris symptoms. Thus, heart rate control is an important therapeutic strategy in coronary artery disease and, for example, chronic heart failure. The pacemaker current I(f) plays a central role in determining spontaneous activity of the sinus node. Ivabradine, a selective inhibitor of the I(f) channel, reduces heart rate without any effect on cardiac contractility and without lowering blood pressure. While beta-blockers remain the first choice for heart rate reduction, in cases of adverse effects ivabradine may be used to treat stable angina pectoris. Studies evaluating possible further uses, for example in heart failure or after acute myocardial infarction, are still warranted.
心率升高与心血管死亡率增加相关。降低心率可优化心肌耗氧量并减轻心绞痛症状。因此,心率控制是冠状动脉疾病以及如慢性心力衰竭等疾病的重要治疗策略。起搏电流I(f)在决定窦房结的自发活动中起核心作用。伊伐布雷定是I(f)通道的选择性抑制剂,可降低心率,对心脏收缩力无任何影响,且不降低血压。虽然β受体阻滞剂仍是降低心率的首选药物,但在出现不良反应的情况下,伊伐布雷定可用于治疗稳定型心绞痛。评估其可能的进一步用途(如用于心力衰竭或急性心肌梗死后)的研究仍有必要。